Cite
HARVARD Citation
Fredrikson, S. et al. (2013). A cost-effectiveness analysis of subcutaneous interferon beta-1a 44mcg 3-times a week vs no treatment for patients with clinically isolated syndrome in Sweden. Journal of medical economics. pp. 756-762. [Online].